FindTrial
Sign In

Prospective Clinical Study on the Diagnostic and Therapeutic Value of Artificial Intelligence-Based 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma

Clinical Study on the Diagnostic and Therapeutic Value of Artificial Intelligence-Based 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077803
Enrollment
Unknown
Registered
2023-11-20
Start date
2023-12-01
Completion date
Unknown
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B cell lymphoma

Interventions

Case series:None

Sponsors

Department of Nuclear Medicine, West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.Pathological histology confirmed as DLBCL. 2.Pre-treatment 18F-FDG PET/CT examination conducted. 3.All patients received R-CHOP as the first-line treatment regimen. 4.Complete clinical pathological and follow-up data available

Exclusion criteria

Exclusion criteria: 1.Patients with a history of previous antitumor therapy. 2.Patients with a history of other tumors. 3.Incomplete clinical information or imaging data. 4.Concomitant other malignant tumors

Design outcomes

Primary

MeasureTime frame
Overall survival;progression-free survival;ROC curve;AUC value;—

Countries

China

Contacts

Public ContactRong Tian

Department of Nuclear Medicine, West China Hospital of Sichuan University

rongtiannuclear@126.com+86 189 8060 1586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026